Procedural Characteristics and Late Outcomes of Percutaneous Coronary Intervention in the Workup Pre-TAVR

Faroux, Laurent; Campelo‐Parada, Francisco; Muñoz-García, Érika; Nombela‐Franco, Luis; Fischer, Quentin; Donaint, Pierre; Serra, Violeta; Veiga, Gabriela; Gutiérrez, Enrique; Vilalta, Victòria; Alperi, Alberto; Regueiro, Ander; Asmarats, Lluís; Ribeiro, Henrique Barbosa; Matta, Anthony; Muñoz-García, Antonio J.; Armijo, Germán; Ureña, Marina; Metz, Damien; Ródenas-Alesina, Eduard; Hernández, José M. de la Torre; Fernández-Nofrerias, Eduard; Pascual, Isaac; Pérez-Fuentes, Pedro; Arzamendi, Dabit; Campanha-Borges, Diego Carter; Val, David del; Couture, Thomas; Rodés‐Cabau, Josep

doi:10.1016/j.jcin.2020.07.009

Cited by 39 publications

(21 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…244 Percutaneous coronary intervention (PCI) and TAVI may be undertaken as combined or staged procedures according to the clinical situation, pattern of CAD, and extent of myocardium at risk. 259 In the SURTAVI trial, there was no significant difference in the primary endpoint (all-cause mortality or stroke at 2-year follow-up) in intermediate-risk patients with severe aortic stenosis and non-complex CAD (SYNTAX score <22) undergoing either TAVI and PCI or SAVR and CABG [16.0% (95% CI, 11.1-22.9) vs. 14% (95% CI, 9.2-21.1); P = 0.62]. 260 Assessing the clinical value of systematic PCI in TAVI patients with significant associated CAD is the objective of ongoing RCTs.…”

Section: Special Patient Populationsmentioning

confidence: 99%

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Vahanian¹,

Beyersdorf²,

Praz³

et al. 2022

EuroIntervention

549

581

View full text Add to dashboard Cite

The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of health care or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and the patient's caregiver where appropriate and/or necessary. Nor do the ESC Guidelines exempt health professionals from taking careful and full consideration of the relevant official updated recommendations or guidelines issued by the competent public health authorities in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

show abstract

Section: Special Patient Populationsmentioning

confidence: 99%

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Vahanian¹,

Beyersdorf²,

Praz³

et al. 2022

EuroIntervention

549

581

View full text Add to dashboard Cite

show abstract

“…Severe aortic stenosis was initially considered a contraindication for PCI. Instead, Goel et al [41] showed that this was feasible without an increase in mortality. A recent multicenter study highlighted that PCI before TAVI is currently performed successfully in most cases even in multivessel disease, left main disease, and calcific stenosis [42] .…”

Section: The Optimal Timing Of Revascularizationmentioning

confidence: 99%

Management of concomitant coronary artery disease and aortic valve stenosis in the era of transcatheter aortic valve treatment

Aurigemma¹,

Romagnoli²,

Bianchini³

et al. 2022

MIS

View full text Add to dashboard Cite

Severe calcific aortic stenosis (AS) and coronary artery disease (CAD) have common risk factors and are frequently encountered in the same patient in clinical practice. CAD has been reported in ≥ 50% of AS patients undergoing both surgical treatment and transcatheter aortic valve implantation (TAVI). In the last two decades, TAVI has been established as a less invasive alternative to surgery. Recently, more and more young and low surgical risk patients undergo TAVI. Despite the high prevalence of CAD in patients treated with TAVI, the management strategy of concomitant CAD in these patients remains an area of considerable uncertainty. This review provides an updated overview of the current knowledge about this topic and offers points for reflection about the best approach to use.

show abstract

“…Even short-term DAPT is associated with a higher rate of serious adverse events as compared with single antiplatelet therapy, which is now the standard post-procedural anti-thrombotic therapy after TAVI (65,66). Another concern regarding PCI in patients with AS is the risk of stent-thrombosis and target lesion failure, but recent data have shown that these events are rare in patients treated with PCI before TAVI (67).…”

Section: Is Revascularization Necessary?mentioning

confidence: 99%

Coronary Assessment and Revascularization Before Transcutaneous Aortic Valve Implantation: An Update on Current Knowledge

Sabbah

Engstrøm

Søndergaard

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Transcutaneous aortic valve implantation (TAVI) has led to a paradigm shift in the treatment of severe aortic stenosis (AS) in the elderly and is expanding to still younger and lower-risk patients with severe AS as an alternative to surgical aortic valve replacement (SAVR). While the role of coronary artery bypass grafting with SAVR is well-documented, the analog of percutaneous coronary intervention with TAVI is less so. The aim of this review is to provide an overview of the important challenges in treating severe AS and co-existing coronary artery disease in patients planned for TAVI.

show abstract

Procedural Characteristics and Late Outcomes of Percutaneous Coronary Intervention in the Workup Pre-TAVR

Cited by 39 publications

References 37 publications

2021 ESC/EACTS Guidelines for the management of valvular heart disease

2021 ESC/EACTS Guidelines for the management of valvular heart disease

Management of concomitant coronary artery disease and aortic valve stenosis in the era of transcatheter aortic valve treatment

Coronary Assessment and Revascularization Before Transcutaneous Aortic Valve Implantation: An Update on Current Knowledge

Contact Info

Product

Resources

About